Epigenetics of psychoactive drugs

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 10, 2012, Pages 1349-1358

  Boyadjieva, Nadka ^a,b   Varadinova, Miroslava ^a  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b RUTGERS UNIVERSITY   (United States)

Author keywords

molecular and receptor pharmacology; tissue and cellular pharmacology; whole body pharmacology

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ASENAPINE; ATYPICAL ANTIPSYCHOTIC AGENT; BLONANSERIN; CHLORPROMAZINE; CLOSPIPRAMINE; CLOTIAPINE; CLOZAPINE; DNA METHYLTRANSFERASE 1; FLUPHENAZINE; GLUTAMATE DECARBOXYLASE 67; HALOPERIDOL; ILOPERIDONE; LITHIUM; LOXAPINE; LURASIDONE; METHIONINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PIMOZIDE; PSYCHOTROPIC AGENT; REELIN; S ADENOSYLMETHIONINE; THIORIDAZINE; TIOTIXENE; TRIFLUOPERAZINE; UNINDEXED DRUG; VALPROIC ACID;

AUDITORY HALLUCINATION; BIPOLAR DISORDER; CONFUSION; DEMETHYLATION; DISEASE EXACERBATION; DISEASE SEVERITY; DISORIENTATION; DNA METHYLATION; DNMT1 GENE; DRD2 GENE; DRUG EFFECT; DRUG MECHANISM; ENZYME PHOSPHORYLATION; EPIGENETICS; GAD67 GENE; GENE; GENE EXPRESSION REGULATION; GENE SILENCING; HRT2A GENE; HUMAN; MENTAL DISEASE; NONHUMAN; PERCEPTION DISORDER; PHARMACOGENOMICS; PSYCHOMOTOR RETARDATION; PSYCHOPHARMACOTHERAPY; RELN GENE; REVIEW; SCHIZOPHRENIA; SEIZURE; UNSPECIFIED SIDE EFFECT; VISUAL HALLUCINATION;

ANIMALS; BIPOLAR DISORDER; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONES; HUMANS; MENTAL DISORDERS; PSYCHOTROPIC DRUGS; SCHIZOPHRENIA;

EID: 84865862998     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2012.01475.x     Document Type: Review

References (114)

1. Sharma RP, et al,. Histone deacetylase 1 expression is increased in the prefrontal cortex of schizophrenia subjects: analysis of the National Brain Databank microarray collection. Schizophr Res 2008; 98: 111-117. (Pubitemid 350235899)
2. An W,. Histone acetylation and methylation: combinatorial players for transcriptional regulation. Subcell Biochem 2007; 41: 351-369.
3. Rice JC, Allis CD,. Histone methylation versus histone acetylation: new insights into epigenetic regulation. Curr Opin Cell Biol 2001; 13: 263-273. (Pubitemid 32429490)
4. Zhang Y, Reinberg D,. Transcription regulation by histone methylation: interplay between different covalent modifications of the core histone tails. Genes Dev 2001; 15: 2343-2460.
5. Cedar H, Bergman Y,. Linking DNA methylation and histone modification: patterns and paradigms. Nat Rev Genet 2009; 10: 295-304.
6. Ha M, et al,. Coordinated histone modifications are associated with gene expression variation within and between species. Genome Res 2011; 21: 590-598.
7. Abdolmaleky HM, et al,. Methylomics in psychiatry: modulation of gene-environment interactions may be through DNA methylation. Am J Med Genet 2004; 127B: 51-59. (Pubitemid 38542313)
8. Baylin SB, et al,. Aberrant patterns of DNA methylation, chromatin formation and gene expression in cancer. Hum Mol Genet 2001; 10: 687-692. (Pubitemid 32331576)
9. Herman JC, Baylin SB,. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 2003; 349: 2042-2054. (Pubitemid 37448928)
10. Noh JS, et al,. DNA methyltransferase 1 regulates reelin mRNA expression in mouse primary cortical cultures. Proc Natl Acad Sci U S A 2005; 102: 1749-1754.
11. Jones P, Takai D,. The role of DNA methylation in mammalian epigenetics. Science 2001; 293: 1068-1070. (Pubitemid 32758075)
12. Dong E, et al,. Clozapine and sulpiride but not haloperidol or olanzapine activate nuclear DNA-demethylation in the brain. Proc Natl Acad Sci U S A 2008; 105: 13614-13619.
13. Abdolmaleky HM, et al,. Hypermethylation of the reelin (RELN) promoter in the brain of schizophrenic patients: a preliminary report. Am J Med Genet 2005; 134B: 60-66. (Pubitemid 40411111)
14. Kundakovic M, et al,. The reelin and GAD67 promoters are activated by epigenetic drugs that facilitate the disruption of local repressor complexes. Mol Pharmacol 2009; 75: 342-354.
15. Levenson JM, et al,. The role of reelin in adult synaptic function and the genetic and epigenetic regulation of the reelin gene. Biochim Biophys Acta 2009; 1779: 422-431.
16. Guidotti A, et al,. Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study. Arch Gen Psychiatry 2000; 57: 1061-1069.
17. Guidotti A, et al,. Epigenetic GABAergic targets in schizophrenia and bipolar disorder. Neuropharmacology 2011; 60: 1007-1016.
18. Qui S, et al,. A fresh look at an ancient receptor family: emerging roles for low density lipoprotein receptors in synaptic plasticity and memory formation. Neurobiol Learn Mem 2006; 85: 16-29.
19. Guidotti A, et al,. GABAergic dysfunction in schizophrenia: new treatment strategies on the horizon. Psychopharmacol (Berl) 2005; 180: 191-205. (Pubitemid 40909664)
20. Straub RE, et al,. Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression. Mol Psychiatry 2007; 12: 854-869. (Pubitemid 47347790)
21. Shifman S, et al,. Genome-wide association identifies a common variant in the reelin gene that increases the risk of schizophrenia only in women. PLoS Genet 2008; 4: e28.
22. Torrey EF, et al,. Neurochemical markers for schizophrenia, bipolar disorder, and major depression in postmortem brains. Biol Psychiatry 2005; 57: 252-260. (Pubitemid 40187369)
23. Grayson DR, et al,. Reelin promoter hypermethylation in schizophrenia. Proc Nat Acad Sci U S A 2005; 102: 9341-9346. (Pubitemid 40923565)
24. Huang HS, Akbarian S,. Gad1 mRNA expression and DNA methylation in prefrontal cortex of subjects with schizophrenia. PLoS ONE 2007; 2: e809.
25. Ptak C, Petronis A,. Epigenetic approaches to psychiatric disorders. Dialogues Clin Neurosci 2010; 12: 25-35.
26. Veldic M, et al,. DNA-methyltransferase 1 mRNA is selectively overexpressed in telencephalic GABAergic interneurons of schizophrenia brains. Proc Natl Acad Sci U S A 2004; 101: 348-353. (Pubitemid 38084253)
27. Zhubi A, et al,. An upregulation of DNA-methyltransferase 1 and 3a expressed in telencephalic GABAergic neurons of schizophrenia patients is also detected in peripheral blood lymphocytes. Schizophr Res 2009; 111: 115-122.
28. Grayson DR, et al,. The human reelin gene: transcription factors (+), repressors (-) and the methylation switch (±) in schizophrenia. Pharmacol Ther 2006; 111: 272-286. (Pubitemid 43765535)
29. Wyatt RJ, et al,. Biochemical and sleep studies of schizophrenia: a review of the literature-1960-70. Schiz Bull 1971; 4: 10-44.
30. Brune GG, Himwich HE,. Effects of methionine loading on the behavior of schizophrenic patients. J Nerv Ment Dis 1962; 134: 447-450.
31. Cohen SM, et al,. The administration of methionine to chronic schizophrenic patients: a review of ten studies. Biol Psychiatry 1974; 8: 209-225.
32. Dong E, et al,. Reelin and glutamic acid decarboxylase 67 promoter remodeling in an epigenetic methionine-induced mouse model of schizophrenia. Proc Natl Acad Sci U S A 2005; 102: 12578-12583. (Pubitemid 41266401)
33. Tremolizzo L, et al,. Valproate corrects the schizophrenia-like epigenetic behavioral modifications induced by methionine in mice. Biol Psychiatry 2005; 57: 500-509. (Pubitemid 40311985)
34. Dong E, et al,. Histone hyperacetylation induces demethylation of reelin and 67-kDa glutamic acid decarboxylase promoters. Proc Natl Acad Sci U S A 2007; 104: 4676-4681. (Pubitemid 47186284)
35. Kundakovic M, et al,. DNA methyltransferase inhibitors coordinately induce expression of the human reelin and glutamic acid decarboxylase 67 genes. Mol Pharmacol 2007; 71: 644-653. (Pubitemid 46294076)
36. Tremolizzo L, et al,. An epigenetic mouse model for molecular and behavioral neuropathologies related to schizophrenia vulnerability. Proc Natl Acad Sci U S A 2002; 99: 17095-17100. (Pubitemid 36034104)
37. Grayson DR, et al,. From transmethylation to cytosine methylation: evolution of the methylation hypothesis of schizophrenia. Epigenetics 2009; 4: 144-149.
38. Guidotti A, et al,. S-adenosyl methionine and DNA methyltransferase-1 mRNA overexpression in psychosis. Neuroreport 2007; 18: 57-60. (Pubitemid 46183390)
39. Athanasiou MC, et al,. Discovery and utilization of haplotypes for pharmacogenetic studies of psychotropic drug response. Psychiatr Genet 2002; 12: 89-96. (Pubitemid 34787839)
40. McEvoy JP, et al,. Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163: 600-610. (Pubitemid 44464569)
41. Arranz MJ, de Leon J,. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 2007; 12: 707-747. (Pubitemid 47172693)
42. Nnadi CU, Malhotra AK,. Individualizing antipsychotic drug therapy in schizophrenia: the promise of pharmacogenetics. Curr Psychiatry Rep 2007; 9: 313-318. (Pubitemid 47490003)
43. Yamanouchi Y, et al,. Effect of DRD2, 5-HT2A, and COMT genes on antipsychotic response to risperidone. Pharmacogenomics J 2003; 3: 356-361. (Pubitemid 38072174)
44. Arranz M, et al,. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 1995; 346: 281-282.
45. Arranz MJ, et al,. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res 1998; 32: 93-99. (Pubitemid 28364714)
46. Strous RD, et al,. Association of the dopamine receptor interacting protein gene, NEF3, with early response to antipsychotic medication. Int J Neuropsychopharmacol 2007; 10: 321-333. (Pubitemid 46701000)
47. Farah A,. Atypicality of atypical antipsychotics. Prim Care Companion J Clin Psychiatry 2005; 7: 268-274. (Pubitemid 44371604)
48. Culpepper L,. A roadmap to key pharmacologic principles in using antipsychotics. Prim Care Companion J Clin Psychiatry 2007; 9: 444-454. (Pubitemid 350278284)
49. Leucht S, et al,. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009; 373: 31-41.
50. Seeman P,. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002; 47: 27-38. (Pubitemid 34302921)
51. Horacek J, et al,. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs 2006; 20: 389-405.
52. Kelly DL, et al,. Adjunct divalproex or lithium to clozapine in treatment-resistant schizophrenia. Psychiatr Q 2006; 77: 81-95. (Pubitemid 43060798)
53. Polesskaya OO, Sokolov BP,. Differential expression of the 'C' and 'T' alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J Neurosci Res 2002; 67: 812-822. (Pubitemid 34226294)
54. Hurlemann R, et al,. 5-HT2A receptor density is decreased in the at-risk mental state. Psychopharmacology (Berl) 2008; 195: 579-590. (Pubitemid 350160486)
55. Zhu JK,. Active DNA demethylation mediated by DNA glycosylases. Annu Rev Genet 2009; 43: 143-166.
56. Barreto G, et al,. Gadd45a promotes epigenetic gene activation by repair-mediated DNA demethylation. Nature 2007; 445: 671-675. (Pubitemid 46232889)
57. Guidotti A, et al,. Characterization of the action of antipsychotic subtypes on valproate-induced chromatin remodeling. Trends Pharmacol Sci 2009; 30: 55-60.
58. Li J, et al,. Dopamine D2-like antagonists induce chromatin remodeling in striatal neurons through cyclic AMP-protein kinase A and NMDA receptor signaling. Neurochem 2004; 90: 1117-1131. (Pubitemid 39167345)
59. Bertran-Gonzalez J, et al,. Opposing patterns of signaling activation in dopamine D1 and D2 receptor-expressing striatal neurons in response to cocaine and haloperidol. J Neurosci 2008; 28: 5671-5685.
60. Bertran-Gonzalez J, et al,. Histone H3 phosphorylation is under the opposite tonic control of dopamine D2 and adenosine A2A receptors in striatopallidal neurons. Neuropsychopharmacology 2009; 34: 1710-1720.
61. Mill J, et al,. Epigenomic profiling reveals DNA-methylation changes associated with major psychosis. Am J Hum Genet 2008; 82: 696-711. (Pubitemid 351726115)
62. Matrisciano F, et al,. Activation of group II metabotropic glutamate receptors promotes DNA demethylation in the mouse brain. Mol Pharmacol 2011; 80: 174-182.
63. Williams J, et al,. Meta-analysis of association between the 5-HT2a receptor T102C polymorphism and schizophrenia. EMASS Collaborative Group. European Multicentre Association Study of Schizophrenia. Lancet 1997; 349: 1221. (Pubitemid 27190050)
64. Abdolmaleky HM, et al,. Meta-analysis of association between the T102C polymorphism of the 5HT2a receptor gene and schizophrenia. Schizophr Res 2004; 67: 53-62. (Pubitemid 38117091)
65. Abdolmaleky HM, et al,. Genetics and epigenetics in major psychiatric disorders: dilemmas, achievements, applications, and future scope. Am J Pharmacogenomics 2005; 5: 149-160. (Pubitemid 40994274)
66. Sodhi MS, Sanders-Bush E,. Serotonin and brain development. Int Rev Neurobiol 2004; 59: 111-174. (Pubitemid 39752414)
67. Cade JF,. Lithium salts in the treatment of psychotic excitement. Med J Aust 1949; 2: 349-352.
68. Kuratomi G, et al,. Aberrant DNA methylation associated with bipolar disorder identified from discordant monozygotic twins. Mol Psychiatry 2008; 13: 429-441. (Pubitemid 351399814)
69. Jacobson S, et al,. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet 1992; 339: 530-533.
70. Cohen LS, et al,. A reevaluation of risk of in utero exposure to lithium. JAMA 1994; 271: 146-150. (Pubitemid 24020593)
71. Klein PS, Melton DA,. A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci U S A 1996; 93: 8455-8459. (Pubitemid 26269579)
72. Zhang F, et al,. Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium. J Biol Chem 2003; 278: 33067-33077.
73. Manisastry SM, et al,. Early temporal-specific responses and differential sensitivity to lithium and Wnt-3A exposure during heart development. Dev Dyn 2006; 235: 2160-2174. (Pubitemid 44208639)
74. Popkie AP, et al,. Phosphatidylinositol 3-kinase (PI3K) signaling via glycogen synthase kinase-3 (Gsk-3) regulates DNA methylation of imprinted loci. J Biol Chem 2010; 285: 41337-41347.
75. Louvi A, et al,. The derivatives of the Wnt3a lineage in the central nervous system. J Comp Neurol 2007; 504: 550-569. (Pubitemid 47572978)
76. Yu W, et al,. Wnt signalling determines ventral spinal cord cell fates in a time dependent manner. Development 2008; 135: 3687-3696.
77. Hur EM, Zhou FQ,. GSK3 signalling in neural development. Nat Rev Neurosci 2010; 11: 539-551.
78. Ferrero A, et al,. The relationship between the Wnt signaling and the psychiatric diseases. Vertex 2006; 17: 165-171.
79. Garcia-Castro MI, et al,. Ectodermal Wnt function as a neural crest inducer. Science 2002; 297: 848-851. (Pubitemid 34839637)
80. Schmidt C, et al,. The role of Wnt signalling in the development of somites and neural crest. Adv Anat Embryol Cell Biol 2008; 195: 1-64.
81. Lovestone S, et al,. Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci 2007; 30: 142-149. (Pubitemid 46482684)
82. Leng Y, et al,. Synergistic neuroprotective effects of lithium and valproic acid or other histone deacetylase inhibitors in neurons: roles of glycogen synthase kinase-3 inhibition. J Neurosci 2008; 28: 2576-2588. (Pubitemid 351348211)
83. Wada A,. Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3beta, beta-catenin, and neurotrophin cascades. J Pharmacol Sci 2009; 110: 14-28.
84. Belmaker RH, et al,. Behavioral reversal of lithium effects by four inositol isomers correlates perfectly with biochemical effects on the PI cycle. Neuropsychopharmacology 1998; 19: 220-232.
85. Wang Q, et al,. Lithium, an anti-psychotic drug, greatly enhances the generation of induced pluripotent stem cells. Cell Res 2011; 21: 1424-1435.
86. Mori S, et al,. Inhibitory effect of lithium on cAMP dependent phosphorylation system. Life Sci 1996; 59: PL99-P104.
87. Chen G, et al,. Lithium regulates PKC-mediated intracellular cross-talk and gene expression in the CNS in vivo. Bipolar Disord 2000; 2 (Pt 2): 217-236.
88. Quiroz JA, et al,. Novel insights into lithium's mechanism of action: neurotrophic and neuroprotective effects. Neuropsychobiology 2010; 62: 50-60.
89. Göttlicher M, et al,. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation oftransformed cells. EMBO J 2001; 20: 6969-6978. (Pubitemid 34062289)
90. Phiel CJ, et al,. Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J Biol Chem 2001; 276: 36734-36741.
91. McElroy SL, et al,. Valproate in psychiatric disorders: literature review and clinical guidelines. J Clin Psychiatry 1989; 50 (Suppl.): 23-29. (Pubitemid 19092381)
92. Kessing LV, et al,. Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study. Br J Psychiatry 2011; 199: 57-63.
93. Calabrese JR, Delucchi GA,. Phenomenology of rapid cycling manic depression and its treatment with valproate. J Clin Psychiatry 1989; 50 (Suppl.): 30-34. (Pubitemid 19092382)
94. Grunze H, et al,. WFSBP Task Force on treatment guidelines for bipolar disorders the World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry 2010; 11: 81-109.
95. Suzuki T, et al,. Augmentation of atypical antipsychotics with valproic acid. An open-label study for most difficult patients with schizophrenia. Hum Psychopharmacol 2009; 24: 628-638.
96. Bisdorff AR,. Management of vestibular migraine. Ther Adv Neurol Disord 2011; 3: 183-191.
97. Chateauvieux S, et al,. Molecular and therapeutic potential and toxicity of valproic acid. Biomed Biotechnol 2010; 2010 pii: 479364.
98. Ornoy A,. Valproic acid in pregnancy: how much are we endangering the embryo and fetus? Reprod Toxicol 2009; 28: 1-10.
99. Gotfryd K, et al,. The teratogenic potencies of valproic acid derivatives and their effects on biological end-points are related to changes in histone deacetylase and Erk1/2 activities. Basic Clin Pharmacol Toxicol 2011; 109: 164-174.
100. Tung EW, Winn L,. Valproic acid increases formation of reactive oxygen species and induces apoptosis in postimplantation embryos: a role for oxidative stress in valproic acid-induced neural tube defects. Mol Pharmacol 2011; 80: 979-987.
101. Ozkan H, et al,. Severe fetal valproate syndrome: combination of complex cardiac defect, multicystic dysplastic kidney, and trigonocephaly. J Matern Fetal Neonatal Med 2011; 24: 521-524.
102. Turner S, et al,. Teratogenic effects on the neuroepithelium of the CD-1 mouse embryo exposed in utero to sodium valproate. Teratology 1990; 41: 421-442. (Pubitemid 20110442)
103. Milutinovic S, et al,. Valproate induces widespread epigenetic reprogramming which involves demethylation of specific genes. Carcinogenesis 2007; 28: 560-571. (Pubitemid 46523352)
104. Williams RS, et al,. A common mechanism of action for three mood-stabilizing drugs. Nature 2002; 417: 292-295. (Pubitemid 34534711)
105. Monti B, et al,. Biochemical, molecular and epigenetic mechanisms of valproic acid neuroprotection. Curr Mol Pharmacol 2009; 2: 95-109.
106. Marchion DC, et al,. Valproic acid alters chromatin structure by regulation of chromatin modulation proteins. Cancer Res 2005; 65: 3815-3822. (Pubitemid 40616361)
107. Langley B, et al,. Remodeling chromatin and stress resistance in the central nervous system: histone deacetylase inhibitors as novel and broadly effective neuroprotective agents. Curr Drug Targets CNS Neurol Disord 2005; 4: 41-50. (Pubitemid 41403313)
108. Rosato RR, et al,. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1. Cancer Res 2003; 63: 3637-3645. (Pubitemid 36793047)
109. Martirosyan A, et al,. Actions of a histone deacetylase inhibitor NSC3852 (5-nitroso-8-quinolinol) link reactive oxygen species to cell differentiation and apoptosis in MCF-7 human mammary tumor cells. J Pharmacol Exp Ther 2006; 317: 546-552.
110. Savickiene J, et al,. The novel histone deacetylase inhibitor BML-210 exerts growth inhibitory, proapoptotic and differentiation stimulating effects on the human leukemia cell lines. Eur J Pharmacol 2006; 549: 9-18. (Pubitemid 44441256)
111. Nightingale KP, et al,. Cross-talk between histone modifications in response to histone deacetylase inhibitors: MLL4 links histone H3 acetylation and histone H3K4 methylation. J Biol Chem 2007; 282: 4408-4416. (Pubitemid 47100929)
112. Ubeda N, et al,. Acute valproate administration impairs methionine metabolism in rats. J Nutr 2002; 132: 2737-2742. (Pubitemid 35013263)
113. Levenson JM, et al,. Regulation of histone acetylation during memory formation in the hippocampus. J Biol Chem 2004; 279: 40545-40559. (Pubitemid 39287646)
114. Peleg S, et al,. Altered histone acetylation is associated with age-dependent memory impairment in mice. Science 2010; 328: 753-756.